(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that it has signed a non-binding letter of intent (LOI) with ProMab Biotechnologies to develop cell based therapies.
- 0 Comments
- FY2017